1
|
On-Demand Bioactivation of Inert Materials With Plasma-Polymerized Nanoparticles. ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2024:e2311313. [PMID: 38483292 DOI: 10.1002/adma.202311313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/27/2023] [Revised: 02/05/2024] [Indexed: 03/22/2024]
Abstract
Conventional gas plasma treatments are crucial for functionalizing materials in biomedical applications, but have limitations hindering their broader use. These methods require exposure to reactive media under vacuum conditions, rendering them unsuitable for substrates that demand aqueous environments, such as proteins and hydrogels. In addition, complex geometries are difficult to treat, necessitating extensive customization for each material and shape. To address these constraints, an innovative approach employing plasma polymer nanoparticles (PPN) as a versatile functionalization tool is proposed. PPN share similarities with traditional plasma polymer coatings (PPC) but offer unique advantages: compatibility with aqueous systems, the ability to modify complex geometries, and availability as off-the-shelf products. Robust immobilization of PPN on various substrates, including synthetic polymers, proteins, and complex hydrogel structures is demonstrated in this study. This results in substantial improvements in surface hydrophilicity. Materials functionalization with arginylglycylaspartic acid (RGD)-loaded PPN significantly enhances cell attachment, spreading, and substrate coverage on inert scaffolds compared to passive RGD coatings. Improved adhesion to complex geometries and subsequent differentiation following growth factor exposure is also demonstrated. This research introduces a novel substrate functionalization approach that mimics the outcomes of plasma coating technology but vastly expands its applicability, promising advancements in biomedical materials and devices.
Collapse
|
2
|
Selective Immunosuppression Targeting the NLRP3 Inflammasome Mitigates the Foreign Body Response to Implanted Biomaterials While Preserving Angiogenesis. Adv Healthc Mater 2023; 12:e2301571. [PMID: 37846971 DOI: 10.1002/adhm.202301571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2023] [Revised: 10/04/2023] [Indexed: 10/18/2023]
Abstract
Medical devices are a mainstay of the healthcare industry, providing clinicians with innovative tools to diagnose, monitor, and treat a range of medical conditions. For implantable devices, it is widely regarded that chronic inflammation during the foreign body response (FBR) is detrimental to device performance, but also required for tissue regeneration and host integration. Current strategies to mitigate the FBR rely on broad acting anti-inflammatory drugs, most commonly, dexamethasone (DEX), which can inhibit angiogenesis and compromise long-term device function. This study challenges prevailing assumptions by suggesting that FBR inflammation is multifaceted, and selectively targeting its individual pathways can stop implant fibrosis while preserving beneficial repair pathways linked to improved device performance. MCC950, an anti-inflammatory drug that selectively inhibits the NLRP3 inflammasome, targets pathological inflammation without compromising global immune function. The effects of MCC950 and DEX on the FBR are compared using implanted polycaprolactone (PCL) scaffolds. The results demonstrate that both DEX and MCC950 halt immune cell recruitment and cytokine release, leading to reduced FBR. However, MCC950 achieves this while supporting capillary growth and enhancing tissue angiogenesis. These findings support selective immunosuppression approaches as a potential future direction for treating the FBR and enhancing the longevity and safety of implantable devices.
Collapse
|
3
|
Plasma polymerized nanoparticles are a safe platform for direct delivery of growth factor therapy to the injured heart. Front Bioeng Biotechnol 2023; 11:1127996. [PMID: 37409168 PMCID: PMC10319252 DOI: 10.3389/fbioe.2023.1127996] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Accepted: 05/31/2023] [Indexed: 07/07/2023] Open
Abstract
Introduction: Heart failure due to myocardial infarction is a progressive and debilitating condition, affecting millions worldwide. Novel treatment strategies are desperately needed to minimise cardiomyocyte damage after myocardial infarction and to promote repair and regeneration of the injured heart muscle. Plasma polymerized nanoparticles (PPN) are a new class of nanocarriers which allow for a facile, one-step functionalization with molecular cargo. Methods: Here, we conjugated platelet-derived growth factor AB (PDGF-AB) to PPN, engineering a stable nano-formulation, as demonstrated by optimal hydrodynamic parameters, including hydrodynamic size distribution, polydisperse index (PDI) and zeta potential, and further demonstrated safety and bioactivity in vitro and in vivo. We delivered PPN-PDGF-AB to human cardiac cells and directly to the injured rodent heart. Results: We found no evidence of cytotoxicity after delivery of PPN or PPN-PDGFAB to cardiomyocytes in vitro, as determined through viability and mitochondrial membrane potential assays. We then measured contractile amplitude of human stem cell derived cardiomyocytes and found no detrimental effect of PPN on cardiomyocyte contractility. We also confirmed that PDGF-AB remains functional when bound to PPN, with PDGF receptor alpha positive human coronary artery vascular smooth muscle cells and cardiac fibroblasts demonstrating migratory and phenotypic responses to PPN-PDGF-AB in the same manner as to unbound PDGF-AB. In our rodent model of PPN-PDGF-AB treatment after myocardial infarction, we found a modest improvement in cardiac function in PPN-PDGF-AB treated hearts compared to those treated with PPN, although this was not accompanied by changes in infarct scar size, scar composition, or border zone vessel density. Discussion: These results demonstrate safety and feasibility of the PPN platform for delivery of therapeutics directly to the myocardium. Future work will optimize PPN-PDGF-AB formulations for systemic delivery, including effective dosage and timing to enhance efficacy and bioavailability, and ultimately improve the therapeutic benefits of PDGF-AB in the treatment of heart failure cause by myocardial infarction.
Collapse
|
4
|
Selective NLRP3 Inflammasome Inhibitor MCC950 Suppresses Inflammation and Facilitates Healing in Vascular Materials. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2023:e2300521. [PMID: 37150865 PMCID: PMC10369291 DOI: 10.1002/advs.202300521] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Subscribe] [Scholar Register] [Received: 01/24/2023] [Revised: 03/31/2023] [Indexed: 05/09/2023]
Abstract
Minimally invasive interventions using drug-eluting stents or balloons are a first-line treatment for certain occlusive cardiovascular diseases, but the major long-term cause of failure is neointimal hyperplasia (NIH). The drugs eluted from these devices are non-specific anti-proliferative drugs, such as paclitaxel (PTX) or sirolimus (SMS), which do not address the underlying inflammation. MCC950 is a selective inhibitor of the NLRP3-inflammasome, which drives sterile inflammation commonly observed in NIH. Additionally, in contrast to broad-spectrum anti-inflammatory drugs, MCC950 does not compromise global immune function due this selective activity. In this study, MCC950 is found to not impact the viability, integrity, or function of human coronary endothelial cells, in contrast to the non-specific anti-proliferative effects of PTX and SMS. Using an in vitro model of NLRP3-mediated inflammation in murine macrophages, MCC950 reduced IL-1β expression, which is a key driver of NIH. In an in vivo mouse model of NIH in vascular grafts, MCC950 significantly enhanced re-endothelialization and reduced NIH compared to PTX or SMS. These findings show the effectiveness of a targeted anti-inflammatory drug-elution strategy with significant implications for cardiovascular device intervention.
Collapse
|
5
|
Macrophage Polarization as a Novel Therapeutic Target for Endovascular Intervention in Peripheral Artery Disease. JACC Basic Transl Sci 2021; 6:693-704. [PMID: 34466756 PMCID: PMC8385566 DOI: 10.1016/j.jacbts.2021.04.008] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Revised: 04/27/2021] [Accepted: 04/27/2021] [Indexed: 11/19/2022]
Abstract
Peripheral artery disease (PAD) has a significant impact on human health, affecting 200 million people globally. Advanced PAD severely diminishes quality of life, affecting mobility, and in its most severe form leads to limb amputation and death. Treatment of PAD is among the least effective of all endovascular procedures in terms of long-term efficacy. Chronic inflammation is a key driver of PAD; however, stents and coated balloons eluting antiproliferative drugs are most commonly used. As a result, neither stents nor coated balloons produce durable clinical outcomes in the superficial femoral artery, and both have recently been associated with significantly increased mortality. This review summarizes the most common clinical approaches and limitations to treating PAD and highlights the necessity to address the underlying causes of inflammation, identifying macrophages as a novel therapeutic target in the next generation of endovascular PAD intervention.
Collapse
Key Words
- BMS, bare-metal stent
- CAD, coronary artery disease
- DES, drug-eluting stent
- FP, femoropopliteal
- IL, interleukin
- MI, myocardial infarction
- PAD, peripheral artery disease
- PTA, percutaneous transluminal angioplasty
- SFA, superficial femoral artery
- TGF, transforming growth factor
- TNF, tumor necrosis factor
- drug-eluting balloon
- drug-eluting stent
- endovascular intervention
- macrophage polarization
- paclitaxel
- peripheral arterial disease
- vascular healing
- vascular inflammation
Collapse
|
6
|
Silk Fibroin Scaffold Architecture Regulates Inflammatory Responses and Engraftment of Bone Marrow-Mononuclear Cells. Adv Healthc Mater 2021; 10:e2100615. [PMID: 33963682 DOI: 10.1002/adhm.202100615] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Indexed: 12/13/2022]
Abstract
Despite being one of the most clinically trialed cell therapies, bone marrow-mononuclear cell (BM-MNC) infusion has largely failed to fulfill its clinical promise. Implanting biomimetic scaffolds at sites of injury prior to BM-MNC infusion is a promising approach to enhance BM-MNC engraftment and therapeutic function. Here, it is demonstrated that scaffold architecture can be leveraged to regulate the immune responses that drive BM-MNC engraftment. Silk scaffolds with thin fibers and low porosity (LP) impairs immune activation in vitro compared with thicker fiber, high porosity (HP) scaffolds. Using the authors' established in vivo bioluminescent BM-MNC tracking model, they showed that BM-MNCs home to and engraft in greater numbers in HP scaffolds over 14 days. Histological analysis reveals thicker fibrous capsule formation, with enhanced collagen deposition in HP compared to LP scaffolds consistent with substantially more native CD68+ macrophages and CD4+ T cells, driven by their elevated pro-inflammatory M1 and Th1 phenotypes, respectively. These results suggest that implant architecture impacts local inflammation that drives differential engraftment and remodeling behavior of infused BM-MNC. These findings inform the future design of biomimetic scaffolds that may better enhance the clinical effectiveness of BM-MNC infusion therapy.
Collapse
|
7
|
Comprehensive Evaluation of the Toxicity and Biosafety of Plasma Polymerized Nanoparticles. NANOMATERIALS 2021; 11:nano11051176. [PMID: 33947114 PMCID: PMC8145910 DOI: 10.3390/nano11051176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Revised: 04/22/2021] [Accepted: 04/23/2021] [Indexed: 11/17/2022]
Abstract
The rapid growth of nanoparticle-based therapeutics has underpinned significant developments in nanomedicine, which aim to overcome the limitations imposed by conventional therapies. Establishing the safety of new nanoparticle formulations is the first important step on the pathway to clinical translation. We have recently shown that plasma-polymerized nanoparticles (PPNs) are highly efficient nanocarriers and a viable, cost-effective alternative to conventional chemically synthesized nanoparticles. Here, we present the first comprehensive toxicity and biosafety study of PPNs using both established in vitro cell models and in vivo models. Overall, we show that PPNs were extremely well tolerated by all the cell types tested, significantly outperforming commercially available lipid-based nanoparticles (lipofectamine) used at the manufacturer’s recommended dosage. Supporting the in vitro data, the systemic toxicity of PPNs was negligible in BALB/c mice following acute and repeated tail-vein intravenous injections. PPNs were remarkably well tolerated in mice without any evidence of behavioral changes, weight loss, significant changes to the hematological profile, or signs of histological damage in tissues. PPNs were tolerated at extremely high doses without animal mortality observed at 6000 mg/kg and 48,000 mg/kg for acute and repeated-injection regimens, respectively. Our findings demonstrate the safety of PPNs in biological systems, adding to their future potential in biomedical applications.
Collapse
|
8
|
Bioactivation of Encapsulation Membranes Reduces Fibrosis and Enhances Cell Survival. ACS APPLIED MATERIALS & INTERFACES 2020; 12:56908-56923. [PMID: 33314916 DOI: 10.1021/acsami.0c20096] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Encapsulation devices are an emerging barrier technology designed to prevent the immunorejection of replacement cells in regenerative therapies for intractable diseases. However, traditional polymers used in current devices are poor substrates for cell attachment and induce fibrosis upon implantation, impacting long-term therapeutic cell viability. Bioactivation of polymer surfaces improves local host responses to materials, and here we make the first step toward demonstrating the utility of this approach to improve cell survival within encapsulation implants. Using therapeutic islet cells as an exemplar cell therapy, we show that internal surface coatings improve islet cell attachment and viability, while distinct external coatings modulate local foreign body responses. Using plasma surface functionalization (plasma immersion ion implantation (PIII)), we employ hollow fiber semiporous poly(ether sulfone) (PES) encapsulation membranes and coat the internal surfaces with the extracellular matrix protein fibronectin (FN) to enhance islet cell attachment. Separately, the external fiber surface is coated with the anti-inflammatory cytokine interleukin-4 (IL-4) to polarize local macrophages to an M2 (anti-inflammatory) phenotype, muting the fibrotic response. To demonstrate the power of our approach, bioluminescent murine islet cells were loaded into dual FN/IL-4-coated fibers and evaluated in a mouse back model for 14 days. Dual FN/IL-4 fibers showed striking reductions in immune cell accumulation and elevated levels of the M2 macrophage phenotype, consistent with the suppression of fibrotic encapsulation and enhanced angiogenesis. These changes led to markedly enhanced islet cell survival and importantly to functional integration of the implant with the host vasculature. Dual FN/IL-4 surface coatings drive multifaceted improvements in islet cell survival and function, with significant implications for improving clinical translation of therapeutic cell-containing macroencapsulation implants.
Collapse
|
9
|
Evaluation of synthetic vascular grafts in a mouse carotid grafting model. PLoS One 2017; 12:e0174773. [PMID: 28355300 PMCID: PMC5371373 DOI: 10.1371/journal.pone.0174773] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2016] [Accepted: 03/15/2017] [Indexed: 11/24/2022] Open
Abstract
Current animal models for the evaluation of synthetic grafts are lacking many of the molecular tools and transgenic studies available to other branches of biology. A mouse model of vascular grafting would allow for the study of molecular mechanisms of graft failure, including in the context of clinically relevant disease states. In this study, we comprehensively characterise a sutureless grafting model which facilitates the evaluation of synthetic grafts in the mouse carotid artery. Using conduits electrospun from polycaprolactone (PCL) we show the gradual development of a significant neointima within 28 days, found to be greatest at the anastomoses. Histological analysis showed temporal increases in smooth muscle cell and collagen content within the neointima, demonstrating its maturation. Endothelialisation of the PCL grafts, assessed by scanning electron microscopy (SEM) analysis and CD31 staining, was near complete within 28 days, together replicating two critical aspects of graft performance. To further demonstrate the potential of this mouse model, we used longitudinal non-invasive tracking of bone-marrow mononuclear cells from a transgenic mouse strain with a dual reporter construct encoding both luciferase and green fluorescent protein (GFP). This enabled characterisation of mononuclear cell homing and engraftment to PCL using bioluminescence imaging and histological staining over time (7, 14 and 28 days). We observed peak luminescence at 7 days post-graft implantation that persisted until sacrifice at 28 days. Collectively, we have established and characterised a high-throughput model of grafting that allows for the evaluation of key clinical drivers of graft performance.
Collapse
|
10
|
Blended Polyurethane and Tropoelastin as a Novel Class of Biologically Interactive Elastomer. Tissue Eng Part A 2016; 22:524-33. [PMID: 26857114 DOI: 10.1089/ten.tea.2015.0409] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
Polyurethanes are versatile elastomers but suffer from biological limitations such as poor control over cell attachment and the associated disadvantages of increased fibrosis. We address this problem by presenting a novel strategy that retains elasticity while modulating biological performance. We describe a new biomaterial that comprises a blend of synthetic and natural elastomers: the biostable polyurethane Elast-Eon and the recombinant human tropoelastin protein. We demonstrate that the hybrid constructs yield a class of coblended elastomers with unique physical properties. Hybrid constructs displayed higher elasticity and linear stress-strain responses over more than threefold strain. The hybrid materials showed increased overall porosity and swelling in comparison to polyurethane alone, facilitating enhanced cellular interactions. In vitro, human dermal fibroblasts showed enhanced proliferation, while in vivo, following subcutaneous implantation in mice, hybrid scaffolds displayed a reduced fibrotic response and tunable degradation rate. To our knowledge, this is the first example of a blend of synthetic and natural elastomers and is a promising approach for generating tailored bioactive scaffolds for tissue repair.
Collapse
|
11
|
Mechanically Robust Plasma-Activated Interfaces Optimized for Vascular Stent Applications. ACS APPLIED MATERIALS & INTERFACES 2016; 8:9635-9650. [PMID: 27015083 DOI: 10.1021/acsami.6b01279] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
The long-term performance of many medical implants is limited by the use of inherently incompatible and bioinert materials. Metallic alloys, ceramics, and polymers commonly used in cardiovascular devices encourage clot formation and fail to promote the appropriate molecular signaling required for complete implant integration. Surface coating strategies have been proposed for these materials, but coronary stents are particularly problematic as the large surface deformations they experience in deployment require a mechanically robust coating interface. Here, we demonstrate a single-step ion-assisted plasma deposition process to tailor plasma-activated interfaces to meet current clinical demands for vascular implants. Using a process control-feedback strategy which predicts crucial coating growth mechanisms by adopting a suitable macroscopic plasma description in combination with noninvasive plasma diagnostics, we describe the optimal conditions to generate highly reproducible, industry-scalable stent coatings. These interfaces are mechanically robust, resisting delamination even upon plastic deformation of the underlying material, and were developed in consideration of the need for hemocompatibility and the capacity for biomolecule immobilization. Our optimized coating conditions combine the best mechanical properties with strong covalent attachment capacity and excellent blood compatibility in initial testing with plasma and whole blood, demonstrating the potential for improved vascular stent coatings.
Collapse
|
12
|
Characterization of Endothelial Progenitor Cell Interactions with Human Tropoelastin. PLoS One 2015; 10:e0131101. [PMID: 26115013 PMCID: PMC4482626 DOI: 10.1371/journal.pone.0131101] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2013] [Accepted: 05/28/2015] [Indexed: 01/23/2023] Open
Abstract
The deployment of endovascular implants such as stents in the treatment of cardiovascular disease damages the vascular endothelium, increasing the risk of thrombosis and promoting neointimal hyperplasia. The rapid restoration of a functional endothelium is known to reduce these complications. Circulating endothelial progenitor cells (EPCs) are increasingly recognized as important contributors to device re-endothelialization. Extracellular matrix proteins prominent in the vessel wall may enhance EPC-directed re-endothelialization. We examined attachment, spreading and proliferation on recombinant human tropoelastin (rhTE) and investigated the mechanism and site of interaction. EPCs attached and spread on rhTE in a dose dependent manner, reaching a maximal level of 56±3% and 54±3%, respectively. EPC proliferation on rhTE was comparable to vitronectin, fibronectin and collagen. EDTA, but not heparan sulfate or lactose, reduced EPC attachment by 81±3%, while full attachment was recovered after add-back of manganese, inferring a classical integrin-mediated interaction. Integrin αVβ3 blocking antibodies decreased EPC adhesion and spreading on rhTE by 39±3% and 56±10% respectively, demonstrating a large contribution from this specific integrin. Attachment of EPCs on N-terminal rhTE constructs N25 and N18 accounted for most of this interaction, accompanied by comparable spreading. In contrast, attachment and spreading on N10 was negligible. αVβ3 blocking antibodies reduced EPC spreading on both N25 and N18 by 45±4% and 42±14%, respectively. In conclusion, rhTE supports EPC binding via an integrin mechanism involving αVβ3. N25 and N18, but not N10 constructs of rhTE contribute to EPC binding. The regulation of EPC activity by rhTE may have implications for modulation of the vascular biocompatibility of endovascular implants.
Collapse
|
13
|
Abstract 387: Bioengineering L-605 Cobalt Chromium Cardiovascular Stent Biomaterial With Plasma Activated Coating, for Proactive Biocompatibility. Arterioscler Thromb Vasc Biol 2015. [DOI: 10.1161/atvb.35.suppl_1.387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Introduction:
Cobalt Chromium alloy L605 is an underlying biomaterial in new generation drug eluting stents (DES) and bare metal stents (BMS). Suboptimal biocompatibility of stents clinically manifest as thrombosis and restenosis. We optimized a plasma coating technology to activate an alloy L605 surface for enhanced biofunctionalization.
Objective:
Alloy L605 flat metal surface modified with plasma activated coating (PAC), covalently binds tropoelastin (TE) in its bioactive state.
In vitro
studies were conducted to assess biocompatibility of modified PAC biomaterial compared to the bare metal alloy L605.
Methods and Results:
The initial water contact angle (Kruss contact angle analyser, DS10) of PAC was 44.4
0
±3.40 and correlating surface energy computed with the Owens-Wendt-Rabel-Ström kinetic model was 62.35±2.4 mJ/m
2
. Thrombogenicity studies with heparinised whole blood (0.5 U/mL, 37
0
C), in a modified chandler loop showed significantly less clot formation at 60 mins for PAC, PAC+TE Vs. L605 surfaces; 2.2±1.01 mg, 3.6±0.85 mg and 10.3±3.26 mg respectively (P<0.05). Static blood assays with platelet rich plasma (PRP) on PAC and PAC+TE surfaces were compared to L605 (figure 1). Samples incubated with tropoelastin and treated with SDS-Elisa (90
0
C, 10 mins), to assess covalent binding showed higher absorbance for PAC vs. L605. Robust adhesion of PAC polymer to L605 was quantified as surface element percentage with energy dispersive X-ray spectroscopy (2 kV, Xray 2000 cps). Future studies will be conducted on an alloy L605 coronary stent platform.
Conclusion:
The plasma coating is hydrophilic and hemocompatible. The PAC technology will be translated to a commercially available alloy L-605 coronary stent platform to establish a pre-clinical model of hemocompatibility
in vitro,
as an alternative to animal model testing. Early events of coagulation and inflammation will be determined via biological evaluation assays of medical devices (ISO 10993-4).
Collapse
|
14
|
|
15
|
The AudioScope: a clinical tool for otoscopic and audiometric examination. Ear Hear 1985; 6:251-4. [PMID: 4054439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
The AudioScope was evaluated both in laboratory and in clinical settings. Audiometric calibration of the instrument proved to be reliable and easy to accomplish. Clinic evaluation with 182 subjects demonstrated that audiometric screening with the AudioScope shows good agreement with conventional, clinical audiometry. The instrument is a useful clinical adjunct to audiometry since it generally categorizes audiogram configuration and level and provides insight into subject cooperation. This information can enhance the efficiency of manual, threshold audiometry, especially in pediatric cases.
Collapse
|
16
|
Reference threshold sound pressure levels for the Welch Allyn AudioScope. THE JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA 1984; 75:1887-1892. [PMID: 6747099 DOI: 10.1121/1.390990] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Abstract
The Welch Allyn AudioScope has been evaluated as an audiometer screening instrument using a threshold, loudness balancing technique. Two sets of eartips have been compared to determine which eartip configuration would yield the most reliable audiometric data. The AudioScope has also been evaluated by the American National Standard Method for Coupler Calibration of Earphones using both sets of eartips, and reference threshold sound pressure levels for the AudioScope were developed by combining the coupler and loudness balance data. The most reliable eartip configuration for audiometric purposes is identified and guidelines for use of the audiometric screening instrument are proposed.
Collapse
|
17
|
Permanent effects of noise exposure on results of a battery of hearing tests. AMERICAN INDUSTRIAL HYGIENE ASSOCIATION JOURNAL 1980; 41:535-41. [PMID: 7405820 DOI: 10.1080/15298668091425239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Industrial noise exposures may result in permanent hearing impairment caused by changes at the inner ear or cochlea. Research at the Environmental Acoustics Laboratory has shown that measurements of audiometric thresholds alone may not be an adequate indicator of hearing changes due to noise exposure, especially in the early stages of developing, noise-induced, hearing impairment. In response to this observation a battery of tests sensitive to several parameters of hearing has been developed at the Environmental Acoustics Laboratory for use in characterizing and identifying auditory effects of noise exposure. Prior to the present investigation, the use of the testing battery had been restricted to the examination of temporary, noise-induced, hearing impairments under carefully controlled laboratory conditions. The present work reports on the use of the testing battery with clinical patients known to have a history of high-level noise exposure. Generally, the usefulness of the testing battery outside of the laboratory setting and with untrained listeners was demonstrated in this investigation. Details of the procedure for presenting the testing battery components are discussed.
Collapse
|
18
|
Hearing protector performance--an update. AMERICAN INDUSTRIAL HYGIENE ASSOCIATION JOURNAL 1980; 41:542-6. [PMID: 7405821 DOI: 10.1080/15298668091425248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
A single-number descriptor, the A-weighted sound pressure level, has been used widely during the last 10 years for the assessment of noise exposure levels. Prior to that time octave band levels were the common means for describing noise exposures. Hearing protector noise reduction data have been presented in various ways to facilitate the calculation of exposure levels while wearing hearing protectors. This paper describes both single-number and octave band procedures for presenting hearing protector noise attenuation data and discusses advantages and disadvantages of each.
Collapse
|
19
|
Noise attenuation characteristics of the MX-41/AR and the Telephonics circumaural audiometric headsets. JOURNAL OF THE AMERICAN AUDIOLOGY SOCIETY 1978; 4:1-5. [PMID: 721665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Masking from background noise is often a serious problem when hearing levels are measured at or near the low reference threshold levels specified in the American National Standards Specifications for Audiometers, ANSI S3.6-1969. Since background noise limits for audiometric test rooms are inversely related to the noise reduction characteristics of the earphone/cushion assemblies, it is important that these units have significant and consistent attenuation properties. This paper reports the noise reduction characteristics measured for the conventional TDH-39 earphone mounted in the supra-aural MX-41/AR cushion and for the new TDH-50 Telephonics circumaural headset. The circumaural headset was found to produce an average of about 10 dB more noise attenuation than did a well-adjusted supra-aural device, and the circumaural headset provided much more consistent test-retest noise reduction characteristics. Theoretical aspects of headband force as well as the implications of attenuation measurements for test room recommendations are discussed.
Collapse
|
20
|
Loudness Discrimination Index (LDI): a test for the early detection of noise susceptible individuals. AMERICAN INDUSTRIAL HYGIENE ASSOCIATION JOURNAL 1977; 38:333-7. [PMID: 900016 DOI: 10.1080/0002889778507626] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Work has been completed at the Environmental Acoustics Laboratory during the past year on developing an industrially feasible Loudness Discrimination Index (LDI) Test. Data obtained on experimental subjects who had been exposed to brief, high-level sound showed that the maximum Loudness Discrimination Index Shift (LDIS-Max.) is a valid and reliable indicator of temporary, noise-induced, hearing change. This test is better suited to industrial usage than the traditional TTS test. Suggestions for the implementation of LDI testing in the industrial setting are discussed.
Collapse
|
21
|
The effect of high level sound exposure on the loudness difference limen. AMERICAN INDUSTRIAL HYGIENE ASSOCIATION JOURNAL 1976; 37:628-35. [PMID: 998497 DOI: 10.1080/0002889768507535] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Currently used threshold audiograms fail to detect the early stages of noise-induced hearing impairment. Threshold shifts may reach 10 to 15 dB before the impairment is detected. Loudness difference limen and critical band phenomena may provide an earlier and more sensitive test for such hearing impairment. Data is reported which shows that the difference limen shift (DLS) due to noise persists longer than temporary threshold shift (TTS). These findings suggest that DLS may be a more feasible tool for industrial use than either TTS or monitoring audiometry.
Collapse
|
22
|
A procedure for the early detection of noise-susceptible individuals. AMERICAN INDUSTRIAL HYGIENE ASSOCIATION JOURNAL 1976; 37:52-5. [PMID: 1246949 DOI: 10.1080/0002889768507407] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Currently used threshold audiograms fail to detect the early stages of noise-induced hearing impairment. Threshold shifts may reach 10 to 15 dB before the impairment is detected. Loudness difference limen and critical band phenomena should provide an earlier and more sensitive test for such hearing impairment.
Collapse
|
23
|
Personal ear protection evaluation--present and future. AMERICAN INDUSTRIAL HYGIENE ASSOCIATION JOURNAL 1971; 32:753-6. [PMID: 5137932 DOI: 10.1080/0002889718506536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
24
|
Standardization of normal hearing thresholds. JOURNAL OF OCCUPATIONAL MEDICINE. : OFFICIAL PUBLICATION OF THE INDUSTRIAL MEDICAL ASSOCIATION 1968; 10:67-71. [PMID: 5640745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
25
|
Noise in the news. AMERICAN INDUSTRIAL HYGIENE ASSOCIATION JOURNAL 1965; 26:615-8. [PMID: 5879997 DOI: 10.1080/00028896509342782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|